Combination chemotherapy for advanced endometrial cancer. An evaluation of three regimens
- 15 June 1982
- Vol. 49 (12), 2441-2445
- https://doi.org/10.1002/1097-0142(19820615)49:12<2441::aid-cncr2820491203>3.0.co;2-q
Abstract
In patients with advanced uterine corpus carcinoma treated with the combination chemotherapy of megestrol, cyclophosphamide, and doxorubicin (MCA) or with this combination and 5-fluorouracil (MCAF), the overall response rate was 22%. There was no significant difference in response rates between the two regimens. There is some indication that survival was longer in ambulatory patients who were treated with MCA, but this combination produced more hematologic toxicity than MCAF. Patients unsuitable for treatment with doxorubicin received megestrol, 1-phenylalanine mustard, and 5-fluorouracil (MLF), which produced objective responses in 2 of 12 patients.This publication has 4 references indexed in Scilit:
- Carcinoma of the endometrium: Effect of stage and grade on survivalCancer, 1978
- Doxorubicin-cyclophosphamide: Effective chemotherapy for advanced endometrial adenocarcinomaAmerican Journal of Obstetrics and Gynecology, 1977
- Nonhormonal chemotherapy of endometrial adenocarcinoma: A reviewCancer, 1974
- Hydroxyprogesterone caproate therapy in advanced endometrial cancerCancer, 1971